AXIL Brands, Inc. Receives Prestigious Features in Leading Military Publications
AXIL's cutting-edge hearing solutions draw acclaim for innovation and performance
LOS ANGELES, May 30, 2025 (GLOBE NEWSWIRE) -- AXIL Brands, Inc. ('AXIL' or the 'Company')(NYSE American: AXIL), a leader in innovative hearing protection, hearing enhancement, and wireless technology, is proud to announce its recent recognition in esteemed military and technology media outlets. Renowned publications including Military Times, Marine Corps Times, Air Force Times and Navy Times spotlighted AXIL's groundbreaking products in a series of articles. Additionally, the article was syndicated with Yahoo Tech.
The features showcase how AXIL's innovative hearing protection and enhancement solutions cater to the unique demands of military personnel, outdoor enthusiasts, and professionals operating in high-intensity environments. The articles explore AXIL's commitment to providing cutting-edge technology, superior comfort, and unparalleled performance in hearing protection gear.
'These features reaffirm what we've always believed,' says Tyler Smith, Axil's national sales director. 'Our mission is to revolutionize hearing protection and spatial awareness for those who rely on clarity and safety in extreme environments. We're honored to have our products recognized by trusted media outlets that resonate with military professionals and technology enthusiasts alike.'
AXIL products redefine tactical awareness by integrating state-of-the-art technology with practical, field-tested features that enhance performance in critical environments. Designed with advanced digital sound processing, AXIL's earplugs, earmuffs, and earbuds provide unparalleled hearing protection while simultaneously amplifying essential sounds. This ensures users can maintain full situational awareness during high-intensity activities. Whether identifying subtle environmental cues in military operations or maintaining focus in the great outdoors, AXIL's gear offers clarity and precision like never before.
To learn more about AXIL's industry-leading hearing solutions, visit www.goaxil.com. For direct links to the media features, check out the following outlets:
Military Times Feature
Marine Corps Times Feature
Air Force Times Feature
Navy Times Feature
Yahoo Tech Feature
About AXIL BrandsAXIL Brands (NYSE American: AXIL) is an emerging global consumer products company. The Company is a manufacturer and marketer of premium hearing enhancement and protection products, including ear plugs, earmuffs, and ear buds, under the AXIL® brand and premium hair and skincare products under its in-house Reviv3® brand - selling products in the United States, Canada, the European Union, and throughout Asia.
To learn more, please visit the Company's AXIL® website at www.axilbrands.com and its Reviv3® website at www.reviv3.com.
Forward-Looking StatementsThis press release contains a number of forward-looking statements within the meaning of the federal securities laws. The use of words such as 'anticipate,' 'believe,' 'expect,' 'continue,' 'will,' 'prepare,' 'should,' and 'focus,' among others, generally identify forward-looking statements. These forward-looking statements are based on currently available information, and management's beliefs, intentions, strategies, projections, and current expectations concerning future events, including, but not limited to, any statements regarding the Company's anticipated offline expansion, anticipated revenue mix and market share, strategic partnerships and distribution channels, and the potential divestiture of the Company's hair and skin care business, which may not occur in a timely manner, or at all. These forward-looking statements are subject to a number of significant risks and uncertainties, many of which are beyond management's control and may cause the Company's results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that could cause actual results to differ materially from those in the forward-looking statements include, among other things: (i) the Company's ability to grow its net sales and operations, including developing new products and expanding internationally, and perform in accordance with any guidance; (ii) our ability to generate sufficient revenue to support the Company's operations and to raise additional funds or obtain other forms of financing as needed on acceptable terms, or at all; (iii) potential difficulties or delays the Company may experience in implementing its cost savings and efficiency initiatives; (iv) the Company's ability to compete effectively with other hair and skincare companies and hearing enhancement and protection companies; (v) the concentration of the Company's customers, potentially increasing the negative impact to the Company by changing purchasing or selling patterns; (vi) changes in laws or regulations in the United States and/or in other major markets, such as China, in which the Company operates, including, without limitation, with respect to taxes, tariffs, trade policies or product safety, which may increase the Company product costs and other costs of doing business, and reduce the Company's earnings; (vii) the Company's ability to engage in strategic partnerships and expand its distribution and retail channels; and (viii) the impact of unstable market and general economic conditions on the Company's business, financial condition and stock price, including inflationary cost pressures, the possibility of an economic recession and other macroeconomic factors, geopolitical events, and uncertainty, decreased discretionary consumer spending, supply chain disruptions and constraints, labor shortages, ongoing economic disruption, including the effects of the Ukraine-Russia conflict and the Israel-Hamas conflict, and other downturns in the business cycle or the economy. There can be no assurance as to any of these matters, and potential investors are urged to consider these factors carefully in evaluating the forward-looking statements. Other important factors that may cause actual results to differ materially from those expressed in the forward-looking statements are discussed in the Company's filings with the U.S. Securities and Exchange Commission. In addition, the Company's estimates of the addressable market for its products may prove to be inaccurate, and the projected demand for the Company's products could differ materially from actual demand. These forward-looking statements speak only as of the date hereof. Except as required by law, the Company does not assume any obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.
Investor Relations:Media Relations:Todd McKnight(917) 349-2175investors@goaxil.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
40 minutes ago
- Business Upturn
Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde® regimen in metastatic pancreatic adenocarcinoma
Phase III NAPOLI 3 trial is the largest and has the longest follow-up for an interventional study in metastatic pancreatic adenocarcinoma 1 Post-hoc analysis of NAPOLI 3 study determined characteristics associated with long-term survival, with median overall survival of 19.5 months amongst long-term survivors receiving Onivyde ® plus oxaliplatin, fluorouracil and leucovorin (NALIRIFOX) regimen as a first-line therapy 2 Dose reductions and/or treatment delays for the management of adverse events enabled patients to stay on treatment longer and achieve high cumulative doses of liposomal irinotecan and oxaliplatin 2 PARIS, France, 31 May 2025 – Late-breaking (LBA4175) post-hoc analysis data from the Phase III NAPOLI 3 study were presented today at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. These results found a median overall survival (mOS) of 19.5 months among long-term survivors (n=15) with metastatic pancreatic adenocarcinoma (mPDAC) treated with the Onivyde ® (irinotecan liposome injection) plus oxaliplatin, fluorouracil and leucovorin (NALIRIFOX) regimen as a first-line treatment (n=120), with younger age at diagnosis, and certain tumor and metastasis locations associated with long-term survivorship. 2 Pancreatic adenocarcinoma (PDAC) is the most common type of cancer that forms in the pancreas, with more than 60,000 people diagnosed annually in the U.S. and nearly 500,000 people globally.3 , 4 It is often detected after the disease has spread to other parts of the body (metastatic or stage IV)5 and fewer than 20% of people diagnosed with metastatic pancreatic adenocarcinoma (mPDAC) survive longer than one year. 5 , 6 Overall, pancreatic cancer has the lowest five-year survival rate of all cancer types globally and in the U.S. 5 , 6 'When people are diagnosed with metastatic pancreatic adenocarcinoma, the most important question remains: how long will they have with their loved ones,' said Dr. Vincent Chung, Medical Oncologist, City of Hope. 'Findings from the NAPOLI 3 post-hoc analysis provide important context on long-term overall survival with the Onivyde (NALIRIFOX) treatment regimen.' The analysis included patients who survived for 18 months or longer (N=15), with findings showing long-term survivors living with mPDAC had a mOS of 19.5 months (interquartile range [IQR]: 18.8–22.6). 2 Clinical and pathological factors of long-term survivors included younger than average age at time of diagnosis (median age 61.0 (IQR: 49.0–70.5) as well as tumor location. 2 Fewer patients had tumors in the head or tail of the pancreas (53.3% had the main pancreatic tumor located in the body of the pancreas), a substantial proportion had liver metastasis (66.7%) and ≥3 metastatic sites (53.3%). 2 Additionally, findings indicate dose reduction and treatment delays resulted in prolonged exposure and higher cumulative doses of the Onivyde (NALIRIFOX) regimen. 1 Liver metastasis and ≥3 metastatic sites, dose modifications and an otherwise good clinical profile enabled people to achieve a long mOS. 2 Consideration should be taken when interpreting these results as a post-hoc analysis with a small sample size. 'Data from the Phase III NAPOLI 3 trial were the first positive data of its kind in a decade and continue to reinforce the potential for long-term outcomes with the Onviyde (NALIRIFOX) regimen,' said Sandra Silvestri, MD, PhD, Executive Vice President, Chief Medical Officer, Ipsen. 'With people on average living just 4-6 months following diagnosis with pancreatic adenocarcinoma, these data help us to understand the characteristics associated with long-term survival seen in the NAPOLI trial, an important advancement for this difficult-to-treat cancer where data of this kind are scarce.' ENDS About Onivyde (irinotecan liposome injection) Onivyde is a long-circulating liposomal topoisomerase inhibitor. In Onivyde, irinotecan is enclosed in tiny fat particles called liposomes which accumulate in the tumor and release slowly over time. Onivyde is administered via intravenous infusion over 90 minutes every two weeks with recommendations on dosing modifications. Onivyde, as part of the NALIRIFOX regimen (combined with oxaliplatin, fluorouracil (FU) and leucovorin (LV)), is for people living with mPDAC who are treatment naïve or used in combination with FU and LV following gemcitabine-based therapy. Onivyde is not indicated as a single agent for the treatment of adult patients with metastatic pancreatic adenocarcinoma. Ipsen has exclusive commercialization rights for the current and potential future indications for Onivyde in the U.S. Servier, an independent international pharmaceutical company governed by a foundation and with an international presence in 140 countries, is responsible for the commercialization of Onivyde outside of the U.S., Taiwan and Canada. PharmaEngine is a commercial stage oncology company headquartered in Taipei and is responsible for the commercialization of Onivyde in Taiwan. About NAPOLI 3 Study NAPOLI 3 is a randomized, open-label Phase III trial of an Onivyde treatment regimen (NALIRIFOX) in treatment-naïve mPDAC. NAPOLI 3 enrolled 770 patients across 187 trial site locations in 18 countries across Europe, North America, South America, Asia, and Australia. Patients were randomized to receive Onivyde plus oxaliplatin, fluorouracil and leucovorin (NALIRIFOX regimen; n=383) twice in a month (days 1 and 15 of 28-day cycle) compared to an injection of nab-paclitaxel and gemcitabine (n=387) administered three times a month (days 1, 8, 15 of a 28-day cycle) . About Ipsen We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 100 countries. Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit Ipsen Media contacts Investors Khalid Deojee | +33 666019526 | [email protected] Media Disclaimers and/or Forward-Looking Statements The forward-looking statements, objectives and targets contained herein are based on Ipsen's management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen's future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words 'believes', 'anticipates' and 'expects' and similar expressions are intended to identify forward-looking statements, including Ipsen's expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external-growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation; global trends toward healthcare cost containment; technological advances, new medicine and patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval; Ipsen's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen's patents and other protections for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsen's activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen's partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen's business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen's business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen's latest Universal Registration Document, available on References 1 Wainberg et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet. 2023 Oct 7;402(10409):1272-1281. 2 Chung et al. NAPOLI 3 phase 3 study of NALIRIFOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): final overall survival (OS) analysis and characteristics of the long-term survivors. As presented at ASCO Congress 2025 Chicago, USA 3 American Cancer Society – Cancer Facts and Figures 2024. Available : 4 5 Orth, M., Metzger, P., Gerum, S. et al. Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. Radiat Oncol 14, 141 (2019). Attachment Ipsen PR_ASCO NAPOLI_31052025 Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Yahoo
an hour ago
- Yahoo
AG1 Expands Into Retail With Costco Wholesale (NasdaqGS:COST) Nationwide Partnership
Costco Wholesale recently announced a noteworthy retail partnership with AG1, marking a significant channel expansion into brick-and-mortar stores. This development, alongside the company's strong financial performance, aligns with the broader 1.7% market rise over the past month. Despite a market climbing 11% over the year, Costco's 4.59% increase is likely bolstered by its revenue growth and innovative product launches, such as the DripDrop® Hydration variety pack. These factors collectively contribute positively to the company's momentum and complement the general upward market trend, illustrating a robust overall positioning. Every company has risks, and we've spotted 1 weakness for Costco Wholesale you should know about. The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 26 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement. The recent retail partnership between Costco and AG1 represents a meaningful channel expansion, potentially enhancing revenue and earnings forecasts. This move into brick-and-mortar stores could elevate sales volumes and support e-commerce initiatives, while further boosting Costco's diversification efforts across its international markets. Over the past five years, Costco's total shareholder return of 262.00% underscores its consistent performance and growth strategies, contrasting the more modest 4.59% increase over the last year compared to a rising market. This longer-term return showcases an impressive trajectory, highlighting Costco's ability to generate significant returns to investors. With the price target set at US$1052.04, slightly above the current share price of US$1010.50, analysts view Costco as being relatively fairly priced, aligning closely with projected earnings growth and market expectations. The slight discount to the price target suggests the potential for alignment between corporate growth initiatives and market sentiment. Relative to the consumer retailing industry, Costco's 1-year return of 4.59% reflects a performance under the market's 11.5% gain; however, its 5-year performance highlights a formidable ability to achieve sustained growth. This context helps investors consider both short-term dynamics and longer-term growth opportunities. Gain insights into Costco Wholesale's past trends and performance with our report on the company's historical track record. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:COST. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Williamson County veterinary clinic warns cat owners of deadly Bobcat Fever
FAIRVIEW, Tenn. (WKRN) — A Williamson County veterinary clinic is warning cat owners about the dangers of a deadly, tick-borne disease after seeing a surge in cases over the last two weeks. Bobcat Fever, also known as Cytauxzoonosis, is a deadly parasite transmitted to cats by the Lone Star tick, which is known to have one white dot on it. The parasite normally lives in bobcats without causing illness, however, when domestic cats are infected, they often die within 72 hours of first symptoms, which may include fever, lack of energy, decreased appetite, and yellow skin or eyes, deadly, according to Fairview Animal Clinic. Over the last few weeks, Fairview Animal Clinic has seen nine cases of Bobcat Fever. 'We haven't had this many cases in such a short two-week period, so I'm kind of nervous about what's going to happen over this the rest of the summer since it's a long tick season, and it goes all the way to the fall,' said Dr. Eric Fold, associate veterinarian at Fairview Animal Clinic. More than a dozen arrested by Lebanon police in 'targeted operation' Dr. Simone Godwin, a relief veterinarian at Fairview Animal Clinic, said even with aggressive treatment including hospitalization, antimicrobials, and supportive care, the disease is often fatal. In this recent cluster of cases at Fairview Animal Clinic, 78% of cats died or were euthanized. Of the five that were treated, only one survived. Additionally, one cat who did not receive treatment survived. 'So far, we've only had a 20% success rate, and it's really hard on the cats,' Fold said. 'They're very, very sick, and a lot of owners actually elect to euthanize because of the poor prognosis, the just the state of their cat when they bring it in, and it's pretty expensive. The medications are very, very pricey to obtain.' Fold said early detection is crucial as survival rates drop drastically without treatment. 📧 Have breaking news come to you: → 'We've got to get our cats on the prevention, and if you do notice any signs of illness in your cat, bring it in as fast as you can that way we can get them started,' Fold said. 'We've seen some success with it, but it's still a very difficult disease to try to manage.' Dr. Danielle Grigsby, owner of Fairview Animal Clinic, said keeping cats indoors and on year-round flea and tick prevention is the best way to prevent Bobcat Fever and a host of other issues that outdoor cats are at risk for, like trauma, eating something toxic, and other infections. Since some of the fipronil products can take up to 48 hours to actually kill the tick, Fold said the clinic is recommending some of the prescription-based prevention products, such as the Seresto® Flea and Tick Collar for Cats. 'The problem that we're seeing with the Seresto® collar is that the owners actually aren't keeping them tight enough on the cats so they don't actually have contact with the skin, so it has to be tight enough to actually transmit the medication to the cat,' Fold said. 'Just make sure that you go by the label instructions, but it's usually going to be one to two fingers tight, where you can only slip one or two fingers between the cat and the collar. ⏩ Even though the disease does not affect dogs or humans, veterinary experts said both can carry ticks indoors which could ultimately infect a cat. 'The life expectancy of outdoor cats is only 2-5 years, versus up to 15 for indoor cats, Godwin said. 'Your veterinarian can help you make the best decision on prevention products and lifestyle changes to make sure your cat lives a long and healthy life.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
